Schott plans to invest $1 billion in its pharmaceutical packaging business until 2025.
The German glassmaker said it would build production sites, develop lines and manufacture technology as part of its investment plan around the world.
It cited growing global demand for pharmaceutical packaging, such as vials, syringes, ampoules and cartridges made of Borosilicate glass and polymer as the reason for the investment. The investment includes the construction of a glass tubing production facility in China and a production facility for syringes and containers in Germany.
Investment in additional tanks in India, development of the capacity of producing lines in Germany, increased syringe production capacity in Switzerland and the capacity augmentation in its US facility will play an essential role in Schott investment in its pharma business segments. Meanwhile, a strategic partnership with a high tech Canadian firm will allow for lower quality cost for pharmaceutical companies. Several of the investments will be completed early this year. Other projects such as a new melting tank and syringe greenfield production in India will be ramped up later in 2019.
All other major investments will have an impact over the course of the next five to six years. “These investments will increase global access to safe medications, while supporting the marketing of new pharmaceutical products,” added Dr. Frank Heinricht, Chairman of the Management Board of Schott. Pic Schott is expanding its production facility for pharmaceutical packaging in Müllheim. The groundbreaking ceremony for a new plant for polymer syringes is planned for early 2020.
04.04.2019, Schott AG
News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.